​​​
  1. Day 3: Eris Lifesciences IPO subscribed 3.29 times

Day 3: Eris Lifesciences IPO subscribed 3.29 times

The initial public offering (IPO) of Eris Lifesciences was subscribed 3.29 times on Tuesday, the third day of its offering, with investors bidding for 5.24 crore shares against 1.59 crore shares reserved.

By: | Mumbai | Published: June 21, 2017 3:52 AM
Eris Lifesciences IPO, Eris Lifesciences, Eris Lifesciences investors The initial public offering (IPO) of Eris Lifesciences was subscribed 3.29 times on Tuesday, the third day of its offering, with investors bidding for 5.24 crore shares against 1.59 crore shares reserved.(Reuters)

The initial public offering (IPO) of Eris Lifesciences was subscribed 3.29 times on Tuesday, the third day of its offering, with investors bidding for 5.24 crore shares against 1.59 crore shares reserved. Qualified institutional buyers bid for 4.03 crore shares of the 86.17 lakh shares reserved for them. High net-worth individuals (HNIs) bid for 19.37 lakh shares against 43.08 lakh shares reserved for them, retail investors bid for 100,59,816 shares against 28.72 lakh shares reserved for them and employees bid 1.29 lakh shares against 1.5 lakh shares reserved for them. Eris Lifesciences allotted 1.29 crore equity shares at Rs603 per share, aggregating to Rs779.43 crore, to 21 anchor investors on Thursday. The IPO comprises an offer for sale (OFS) of 2.88 crore equity shares by shareholders. Axis Capital, Citigroup Global Markets, and Credit Suisse Securities India are the book running lead managers to the offer.

Eris Lifesciences develops, manufactures and commercialises branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM, such as cardiovascular, anti-diabetics, vitamins, gastroenterology, and anti-infectives.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

  1. No Comments.

Go to Top